Persistence and compliance to osteoporosis therapy in a fracture liaison service: a prospective cohort study

[1]  D. Rouleau,et al.  Rationale, study design, and descriptive data of the Lucky Bone™ Fracture Liaison Service , 2019, Archives of Osteoporosis.

[2]  Y. Kwan,et al.  A systematic review of factors affecting medication adherence among patients with osteoporosis , 2018, Osteoporosis International.

[3]  F. McAlister,et al.  Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial , 2018, Osteoporosis International.

[4]  S. Greenspan,et al.  How Can We Improve Osteoporosis Care? A Systematic Review and Meta‐Analysis of the Efficacy of Quality Improvement Strategies for Osteoporosis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  M. Danila,et al.  Improving drug adherence in osteoporosis: an update on more recent studies , 2018, Therapeutic advances in musculoskeletal disease.

[6]  Sonal Singh,et al.  Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. , 2018, Bone.

[7]  Eric J Tchetgen Tchetgen,et al.  Multiple Imputation for Incomplete Data in Epidemiologic Studies , 2018, American journal of epidemiology.

[8]  Mark P. MacEachern,et al.  Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis , 2017, Osteoporosis International.

[9]  J. Cauley,et al.  Osteoporosis in the Women's Health Initiative: Another Treatment Gap? , 2017, The American journal of medicine.

[10]  P. Juneau,et al.  Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States , 2017, Archives of Osteoporosis.

[11]  L. Tabatabai,et al.  FRACTURE LIAISON SERVICES: MULTIDISCIPLINARY APPROACHES TO SECONDARY FRACTURE PREVENTION. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[12]  Opinder Sahota,et al.  Fracture liaison services: improving outcomes for patients with osteoporosis , 2017, Clinical interventions in aging.

[13]  S. Maraka,et al.  Bisphosphonates for the prevention and treatment of osteoporosis , 2015, BMJ : British Medical Journal.

[14]  A. Naranjo,et al.  Two-year adherence to treatment and associated factors in a fracture liaison service in Spain , 2015, Osteoporosis International.

[15]  M. Bolster,et al.  Fracture Liaison Services: Promoting Enhanced Bone Health Care , 2014, Current Rheumatology Reports.

[16]  M. Seibel,et al.  Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management , 2014, Osteoporosis International.

[17]  S. Zeger,et al.  The validity of self-reported primary adherence among Medicaid patients discharged from the emergency department with a prescription medication. , 2013, Annals of emergency medicine.

[18]  A. Dobson,et al.  Validity of self-reported osteoporosis in mid-age and older women , 2013, Osteoporosis International.

[19]  K. Tsai,et al.  Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan , 2013, Osteoporosis International.

[20]  J. Eisman,et al.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis , 2013, Osteoporosis International.

[21]  L. Lix,et al.  A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving , 2012, Osteoporosis International.

[22]  Jacques P. Brown,et al.  Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk , 2011, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[23]  C. Cooper,et al.  Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.

[24]  A. Farmer,et al.  A systematic review assessing the effectiveness of interventions to improve persistence with anti-resorptive therapy in women at high risk of clinical fracture. , 2010, Family practice.

[25]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[26]  A. Burden,et al.  Measuring and improving adherence to osteoporosis pharmacotherapy , 2010, Current opinion in rheumatology.

[27]  D. Gold,et al.  Compliance and persistence with osteoporosis medications: A critical review of the literature , 2010, Reviews in Endocrine and Metabolic Disorders.

[28]  J. Brown,et al.  Factors influencing the treatment of osteoporosis following fragility fracture , 2009, Osteoporosis International.

[29]  Wanzhu Tu,et al.  Adherence: Comparison of Methods to Assess Medication Adherence and Classify Nonadherence , 2009, The Annals of pharmacotherapy.

[30]  J. Fernandes,et al.  Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. , 2008, British journal of clinical pharmacology.

[31]  M. Olson,et al.  Loss of treatment benefit due to low compliance with bisphosphonate therapy , 2007, Osteoporosis International.

[32]  J. Fernandes,et al.  Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. , 2007, The Journal of clinical endocrinology and metabolism.

[33]  G. Oster,et al.  Compliance with osteoporosis drug therapy and risk of fracture , 2007, Osteoporosis International.

[34]  H. Quan,et al.  New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. , 2004, Journal of clinical epidemiology.

[35]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[36]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[37]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[38]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[39]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  J. Brown,et al.  The care gap in diagnosis and treatment of women with a fragility fracture , 2007, Osteoporosis International.

[41]  Jacques P. Brown,et al.  clinical practice guidelines for the diagnosis and management of osteoporosis in Canada , 2002 .

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.